Nuformix plc (LON:NFX – Get Free Report)’s stock price hit a new 52-week low during trading on Monday . The stock traded as low as GBX 0.04 ($0.00) and last traded at GBX 0.05 ($0.00), with a volume of 157020219 shares changing hands. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Price Performance
The stock’s 50 day simple moving average is GBX 0.10 and its 200 day simple moving average is GBX 0.15. The firm has a market capitalization of £442,427.40, a P/E ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Intel: Is Now the Time to Be Brave?
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Energy and Oil Stocks Explained
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
